Affymax, Inc. and Takeda Pharmaceutical Co. have entered into an exclusive global agreement to develop and commercialize Affymax’s lead product candidate, Hematide, for the treatment of anemia. The companies will collaborate on the development of the product and co-commercialize Hematide in the U.S., while Takeda will hold an exclusive license to develop and commercialize outside the U.S., including the Japanese market. Under the terms of the agreement, Affymax will receive $105 milli...